2月24日晚，长春高新（000661.SZ）子公司金赛药业宣布，自主研发的GenSci141软膏的临床试验申请已获得国家药监局批准。根据此前公告，GenSci141软膏是金赛药业研发的一款双氢睾酮软膏，主要以旁分泌的方式在靶组织内发挥作用，属于化学药品2.2和2.4类。该药物可用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增生症、特发性原因导致的儿童小阴茎。截至目前，全球尚无一款专门针对儿童小阴茎的药物，因此该软膏备受市场关注。
AboutWhat Happens at YC?ApplyYC Interview GuideFAQPeopleYC BlogCompaniesStartup DirectoryFounder DirectoryLaunch YCLibraryPartnersResourcesStartup SchoolNewsletterRequests for StartupsFor InvestorsVerify FoundersHacker NewsBookfaceSafeFind a Co-FounderStartup JobsLog inApplyUbicloudOpen source alternative to AWS
，推荐阅读WPS下载最新地址获取更多信息
Ahmed, who is a consultant surgeon and also carries out gastric band surgeries, said: "We don't know whether it's the injections that are causing the gallstones, or is it because the injections are causing rapid weight loss, which then in turn causes the gallstones?
[&:first-child]:overflow-hidden [&:first-child]:max-h-full"
Alison Francis,Senior Science Journalist